Welcome to our dedicated page for Erasca news (Ticker: ERAS), a resource for investors and traders seeking the latest updates and insights on Erasca stock.
Erasca, Inc. (NASDAQ: ERAS) is a clinical-stage precision oncology company that reports frequent updates related to its efforts to develop therapies for RAS/MAPK pathway-driven cancers. News about Erasca often centers on progress within its RAS-targeting franchise, including clinical, preclinical, regulatory, and intellectual property developments.
Investors following ERAS news can expect detailed announcements on the advancement of the company’s key product candidates, ERAS-0015 and ERAS-4001. Erasca issues releases on milestones such as investigational new drug (IND) clearances, initiation and progress of Phase 1 trials, and early clinical observations in patients with RAS-mutant and KRAS-mutant solid tumors. The company also reports on patent issuances that extend composition of matter protection for its molecules and on scientific presentations at major oncology and healthcare conferences.
Erasca’s news flow includes quarterly business updates and financial results, typically accompanied by commentary from management on the status of the AURORAS-1 and BOREALIS-1 trials, cash resources, and research and development priorities. The company additionally announces participation in investor conferences hosted by firms such as J.P. Morgan, Evercore, Guggenheim, Stifel, Jefferies, Goldman Sachs, and Morgan Stanley, where its leadership discusses strategy and pipeline progress.
For readers tracking ERAS, this news stream provides insight into how Erasca is advancing its clinical-stage programs targeting RAS and KRAS, how it is building its intellectual property position, and how management frames the opportunities and risks associated with its focus on RAS/MAPK pathway-driven cancers.
Erasca (NASDAQ: ERAS), a clinical-stage precision oncology company focused on developing therapies for RAS/MAPK pathway-driven cancers, has announced its participation in the Bank of America Securities 2025 Health Care Conference. The event will take place at the Encore Hotel in Las Vegas, Nevada. The company's management will deliver a presentation on Wednesday, May 14, 2025, at 2:35 PM Pacific Time and will engage in one-on-one investor meetings. A live audio webcast will be accessible at Erasca.com/events, with a replay available for 30 days following the presentation.
Erasca presented new preclinical data at the 2025 AACR Annual Meeting, highlighting advances in their RAS-targeting cancer therapy franchise. The company showcased two key compounds:
ERAS-0015, a pan-RAS molecular glue, demonstrated:
- 8-21 times greater cyclophilin A binding versus competitor RMC-6236
- Strong anti-tumor activity at lower doses
- Effective tumor tissue distribution
ERAS-4001, a novel pan-KRAS inhibitor, showed:
- Selective targeting of both mutant and wildtype KRAS
- Strong tumor growth inhibition in multiple models
- Promising results when combined with anti-PD-1 or cetuximab
Additionally, the company identified first-in-class direct SHOC2 binders, representing a new approach to block cancer-causing RAS/MAPK pathway signaling. These developments reinforce Erasca's position in precision oncology for RAS/MAPK pathway-driven cancers.
Erasca (NASDAQ: ERAS) has announced three poster presentations at the upcoming 2025 AACR Annual Meeting in Chicago, scheduled for April 25-30, 2025. The presentations will showcase the company's advancements in precision oncology, specifically targeting RAS/MAPK pathway-driven cancers.
The presentations will feature:
- ERAS-0015: A potential best-in-class pan-RAS molecular glue, to be presented on April 27
- ERAS-4001: A pan-KRAS inhibitor showing robust anti-tumor activity, scheduled for April 29
- Novel direct SMP complex inhibitors, representing a potential first-in-class approach to block the RAS/MAPK pathway, to be presented on April 28
All posters will be available on Erasca's website following the presentations.
Erasca (NASDAQ: ERAS) reported its Q4 and full year 2024 financial results, highlighting significant progress in its RAS-targeting oncology programs. The company maintains a strong financial position with $440.5 million in cash and equivalents, expected to fund operations into H2 2027.
Key developments include the advancement of two promising candidates: ERAS-0015 (pan-RAS molecular glue) and ERAS-4001 (pan-KRAS inhibitor), both scheduled to enter clinical trials in 2025. The ongoing Phase 3 SEACRAFT-2 trial for naporafenib in NRASm melanoma is progressing well, with Stage 1 randomized data expected in H2 2025.
Financial results show R&D expenses of $26.1 million for Q4 2024 and $115.4 million for the full year. The company reported a net loss of $32.2 million for Q4 and $161.7 million for the full year 2024, or $(0.69) per share.
Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company focused on developing therapies for RAS/MAPK pathway-driven cancers, has announced its upcoming participation in the Guggenheim Securities SMID Cap Biotech Conference. The event will take place at the Lotte New York Palace in New York.
The company's management will conduct a fireside chat on Thursday, February 6, 2025, at 9:30 am Eastern Time and will engage in one-on-one investor meetings. Interested parties can access a live audio webcast of the presentation through Erasca.com/events, where an archived replay will remain available for 30 days following the event.
Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The conference will be held at the Westin St. Francis Hotel in San Francisco, California.
The company's management will deliver a presentation on Tuesday, January 14, 2025, at 9:45 am Pacific Time and will engage in one-on-one meetings with investors. The presentation will be accessible via a live audio webcast on Erasca.com/events, with a replay available for 30 days following the event.
Erasca specializes in discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
Erasca (ERAS) reported Q3 2024 financial results and business updates, highlighting positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort. The company maintains a strong financial position with $463.3 million in cash and equivalents as of September 30, 2024, expected to fund operations into H1 2027. Q3 net loss was $31.2 million ($0.11 per share). R&D expenses increased to $27.6 million, while G&A expenses were $9.6 million. The company is advancing its RAS targeting franchise with planned IND submissions for ERAS-4001 in Q1 2025 and ERAS-0015 in H1 2025.
Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers, announces its participation in three upcoming investor conferences. The company will present at the Guggenheim Securities Healthcare Innovation Conference in Boston (November 12), the Jefferies London Healthcare Conference (November 20), and the 7th Annual Evercore HealthCONx Conference in Coral Gables (December 4). Management will engage in one-on-one investor meetings, and live audio webcasts will be available on Erasca.com/events, with replays accessible for 90 days.
Erasca (ERAS) reported positive preliminary Phase 1b SEACRAFT-1 trial data for naporafenib plus trametinib in NRASm melanoma, showing a 40% response rate (4/10 patients). The Phase 3 SEACRAFT-2 trial is progressing with randomized data expected in 2025, supported by US and European regulatory alignment for potential approval. The company's RAS targeting franchise, including pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001, remains on track for IND submissions in H1 2025 and Q1 2025, respectively. The treatment demonstrated favorable tolerability with mostly low-grade adverse events, and improved management of dermatological toxicities through mandatory primary prophylaxis.
Erasca, Inc. (Nasdaq: ERAS) announced an upcoming oral presentation of preliminary SEACRAFT-1 Phase 1 data for naporafenib plus trametinib in patients with RAS Q61X mutant solid tumors at the 36th EORTC-NCI-AACR Symposium. Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor. The presentation, scheduled for October 24, 2024, will be given by Dr. Elisa Fontana from Sarah Cannon Research Institute, London.
Erasca is also evaluating naporafenib plus trametinib in the ongoing SEACRAFT-2 pivotal Phase 3 trial in NRAS-mutant melanoma, where favorable survival was previously demonstrated. The company will host a virtual R&D update for investors on October 24, 2024, at 8:30 AM ET, coinciding with the symposium.